Hazem Ghebeh

Overview

Cancer therapies are vastly evolving, and our research in the biology of immune checkpoints and signaling pathways illuminates some of the newest and most promising developments in precision oncology. In our studies, we examine the intrinsic and extrinsic roles of immune checkpoints in cancer cell carcinogenesis.

Enhancing Cancer Care With Immunotherapy

We aim to improve cancer therapy by developing a better combination of immune checkpoint inhibitors with other types of therapy like chemotherapy, targeted therapy or a food supplement. Our goals are to improve patients’ response rate to treatment, and to resolve resistance to therapy. Additionally, we are working to identify biomarkers for patients who would likely benefit from immunotherapy.

Our Team

We are solving problems together to improve cancer care.

Hazem Ghebeh

Senior Scientist / Team Leader

Edward Hitti

Senior Scientist

Tala Bakheet

Scientist

Projects

Deep understanding of scientific questions leads to innovative research.

Biomarkers of Anti-PD-L1 Response.
MYC-Driven Therapy Resistance in TNBC.
Intrinsic PD-L1 in Tumor Progression.
Immune and Stem Cell Profiling in NPC.